Entest Financial Statements From 2010 to 2025
| ETNI Stock | USD 0.0002 0.00 0.00% |
Check Entest Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entest Biomedical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Entest financial statements analysis is a perfect complement when working with Entest Biomedical Valuation or Volatility modules.
Entest |
Entest Biomedical Company EBITDA Analysis
Entest Biomedical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Entest Biomedical EBITDA | 192.11 K |
Most of Entest Biomedical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entest Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Entest Biomedical reported earnings before interest,tax, depreciation and amortization of 192.11 K. This is 100.0% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Entest Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Entest Biomedical's current stock value. Our valuation model uses many indicators to compare Entest Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Entest Biomedical competition to find correlations between indicators driving Entest Biomedical's intrinsic value. More Info.Entest Biomedical is rated # 4 in current valuation category among its peers. It is rated # 5 in shares outstanding category among its peers creating about 43.54 of Shares Outstanding per Current Valuation. Comparative valuation analysis is a catch-all model that can be used if you cannot value Entest Biomedical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Entest Biomedical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Entest Biomedical Financial Statements
Investors use fundamental indicators, such as Entest Biomedical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Entest Biomedical's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China. Entest is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Entest Pink Sheet
Entest Biomedical financial ratios help investors to determine whether Entest Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entest with respect to the benefits of owning Entest Biomedical security.